The short answer: cardiac screening is the single most important gatekeeping step before ibogaine treatment, and the specifics matter far more than a general reassurance that "screening is done." Ask about the exact tests performed, how results are interpreted, who reviews them, what disqualifies a candidate, and how monitoring continues once dosing begins. This article is educational and is not medical advice; any decision about ibogaine treatment should involve your own physician.
1–3: What Screening Actually Involves
1. What tests make up your pre-treatment cardiac screening? A credible answer names a 12-lead ECG and an electrolyte panel specifically, not a vague reference to "medical checks." Ask to see the process in writing before you commit to travel or payment.
A credible provider explains why each test matters rather than reciting a checklist. The 12-lead ECG looks specifically at the QT interval, since ibogaine and its active metabolite noribogaine are known to prolong it, and the electrolyte panel checks potassium and magnesium because imbalances in either can compound cardiac risk during dosing. Ask when in your visit screening happens — ideally well before dosing day, with enough time to act on a concerning result, not squeezed in the morning of treatment when there is little room to change course.
2. Who reviews the results, and what are their qualifications? Ask whether a physician with relevant experience reviews every ECG individually, or whether screening is treated as a formality. The person interpreting the data matters as much as the data itself.
A vague answer such as "our medical team reviews everything" is worth pressing on. Ask specifically whether a physician with cardiology-relevant training personally reads each ECG trace, or whether results are only checked against an automated machine reading. Automated ECG software can miss borderline findings that an experienced clinician would flag, so the human review step is not a formality — it is often the difference between catching a marginal QT prolongation and missing it.
3. What specifically disqualifies someone from treatment? Ask for the program's stated exclusion criteria — prolonged QT interval, certain arrhythmias, unstable cardiac disease, or interacting medications. A program willing to name its exclusions clearly is more trustworthy than one that says "we evaluate case by case" without further detail.
It is also worth asking what happens after a disqualification. A responsible program will say plainly that treatment cannot proceed, explain the specific finding behind that decision, and, where appropriate, suggest you discuss alternatives with your own physician. A program that hints at ways around an exclusion, or suggests the finding is unimportant, is not treating cardiac risk with the seriousness it deserves.
4–6: Medications, Monitoring, and the Noribogaine Tail
4. How do you handle current medications during screening? Ask specifically about medications that can also affect heart rhythm. Any adjustment should be planned with physician supervision well in advance, never instructed as a do-it-yourself step before arrival.
Bring a complete, current list of every medication and supplement, including anything taken occasionally, and be specific about dosages and timing. Some interactions relevant to cardiac risk are not obvious from a drug name alone, which is why this conversation should happen with a physician who can evaluate your full regimen rather than a coordinator working from a general list of known exclusions.
5. What monitoring happens during the dosing session itself? Ask whether continuous cardiac telemetry is used throughout dosing, not just spot checks. This is one of the clearest signals of a program's actual clinical seriousness.
Ask what continuous telemetry actually looks like in practice: is it a monitor physically attached for the full duration of the dosing period, watched in real time by trained staff, with a clear protocol for what happens if an abnormal rhythm appears? A program that can describe this concretely, including who is watching the monitor and what their response threshold is, is giving you a very different answer than one that says monitoring is "available."
6. How long does monitoring continue afterward? Because noribogaine, ibogaine's active metabolite, can remain in the body for days, ask how long telemetry and clinical observation continue after the dosing session ends, and whether that period is included in the program's structure or billed separately.
Ask for a specific number of days, not a general assurance of "a few more days of observation." Programs vary in how they structure this window, and some treat extended monitoring as a core part of the protocol while others treat it as an optional add-on. Understanding this distinction before you commit avoids a situation where you feel medically ready to leave sooner than the program's own safety standards would recommend.
7–8: Emergency Preparedness
7. What emergency equipment and protocols are on site? Ask about resuscitation equipment, the presence of medical staff during dosing, and how quickly a physician can respond if a cardiac event is detected on telemetry.
Ask specifically whether staff on site are trained in advanced cardiac life support, not only basic first aid, and whether a physician is physically present during dosing or only reachable by phone. The gap between "a nurse is present" and "a physician is present and can act immediately" is significant when the concern is a cardiac rhythm abnormality that can develop quickly.
8. How far is the nearest hospital, and what is the transfer plan? Ask for specifics: distance, transport arrangements, and whether the facility has a working relationship with a hospital that can be reached quickly if needed. Documented cardiac risk associated with ibogaine and its metabolites is discussed in published research, including work on ibogaine's cardiac effects, which is part of why this preparedness matters.
9: Licensing and Accountability
9. Which regulator licenses this facility, and can I verify it? Ask which authority licenses the program. In Mexico, health facilities are licensed by COFEPRIS, the federal health regulator, and that claim can be checked rather than taken on trust. A program confident in its screening process should have no hesitation naming its regulator and its cardiac safety procedures in detail. Ask, too, whether the facility undergoes any external inspection beyond initial licensing, and how recently its license has been verified. Regulatory status can change over time, and a program that keeps its documentation current and available on request is signaling that it treats licensing as an ongoing responsibility rather than a one-time credential earned once and never revisited.
If you want to discuss your own situation before deciding, our team is reachable through the contact page.
Why Screening Quality Varies So Much Between Programs
Not every ibogaine provider treats cardiac screening the same way, and the differences are not always visible from a website or a brochure. Some programs contract with an outside cardiologist who reviews every ECG independently before dosing is scheduled; others rely on a general practitioner or a nurse practitioner who applies a simplified checklist. Both may describe themselves as offering "medical screening," but the depth of clinical judgment behind that phrase can differ substantially. Asking who specifically interprets your results, and what their background is, is one of the most direct ways to understand which kind of program you are dealing with.
Cost and screening rigor are also worth thinking about together, even though they should not be conflated. A lower price is not automatically a red flag, and a higher price does not guarantee more thorough screening. What matters is transparency: a program that is willing to itemize what screening includes, name the professionals involved, and explain its exclusion criteria in plain language is giving you the information you need to judge value for yourself, rather than asking you to simply trust that safety is being handled responsibly behind the scenes.
Finally, remember that screening is not a one-way filter designed only to exclude people. A thorough evaluation can also give you useful information about your own health, sometimes surfacing findings unrelated to ibogaine candidacy that are worth discussing with your regular physician regardless of what you decide about treatment. Approaching the screening conversation as an honest, two-way exchange — rather than a hurdle to get past as quickly as possible — tends to produce both safer decisions and a clearer picture of what to expect.
A Short Checklist for Cardiac Screening Questions
- Confirm a 12-lead ECG and electrolyte panel are standard, not optional
- Ask who reviews results and their qualifications
- Get stated exclusion criteria in writing
- Ask how current medications are reviewed and adjusted
- Confirm continuous telemetry during dosing
- Ask how long monitoring continues afterward
- Ask about emergency equipment and hospital transfer plans
- Verify the facility's licensing regulator
For a broader look at how a supervised program is structured overall, see ibogaine treatment at Sanctuary Tulum or read about how to choose an ibogaine treatment center.
Educational content only. This article does not diagnose, treat, or replace care from a licensed physician, and nothing here is a promise of any particular outcome. Never start, stop, or change a prescribed medication without medical supervision.
